Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Clarithromycin on Givinostat Pharmacokinetics (Part 2)
NCT05845567Phase 1Completed
- Sponsor
- Italfarmaco
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of givinostat in Duchenne muscular dystrophy (DMD), sponsored by Italfarmaco. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Givinostat, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Givinostat and 5 more. Started Mar 2022; status: completed.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05845567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845567.